(NYSE: HLN) Haleon's forecast annual revenue growth rate of 3.68% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Haleon's revenue in 2025 is $14,588,311,688.On average, 4 Wall Street analysts forecast HLN's revenue for 2025 to be $134,741,150,236,829, with the lowest HLN revenue forecast at $131,946,478,371,767, and the highest HLN revenue forecast at $137,747,164,069,122. On average, 3 Wall Street analysts forecast HLN's revenue for 2026 to be $141,521,361,351,208, with the lowest HLN revenue forecast at $138,974,738,789,816, and the highest HLN revenue forecast at $143,399,421,684,961.
In 2027, HLN is forecast to generate $147,571,086,478,358 in revenue, with the lowest revenue forecast at $144,549,603,060,825 and the highest revenue forecast at $149,315,198,189,710.